A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment

Volume: 61, Issue: 6, Pages: 1355 - 1363
Published: Feb 7, 2020
Abstract
The pharmacokinetics and safety of single-dose zanubrutinib (80 mg) were assessed in subjects with mild, moderate, and severe hepatic impairment (n = 6 each, Child–Pugh class A, B, and C) relative to healthy controls (n = 11). Zanubrutinib median Tmax was 1.25–2.25 h in all groups. Compared to control group, mean zanubrutinib exposure (AUC0–inf) in the mild and moderate hepatic impairment groups was increased by 1.1- and 1.2-fold, which is...
Paper Details
Title
A phase 1, open-label, single-dose study of the pharmacokinetics of zanubrutinib in subjects with varying degrees of hepatic impairment
Published Date
Feb 7, 2020
Volume
61
Issue
6
Pages
1355 - 1363
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.